spacer
home > ict > winter 2009 > the latin beat
PUBLICATIONS
International Clinical Trials

The Latin Beat

 

The experience of running clinical trials in Latin America has improved markedly in recent years in line with the breadth of resources and expertise now available in the region. Graciela Rácaro at PAREXEL International examines the pace of evolution during the last decade

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

Latin America has evolved as an important area for clinical research, and the industry has shown increasing interest in the emerging region that will serve as a potential new end market for biopharmaceutical products. While clinical trial sponsors used to consider Latin America primarily in large studies or for clinical trials that could not achieve the required patient recruitment on time in ‘traditional’ research countries, more recently they have included the region from the beginning when planning their product development programmes.

The growth of clinical trials in Latin America (which is linked to FDA/EMEA acceptance of foreign research data, a huge pool of potential trial patients, and the globalisation of clinical research) should be assessed not only in terms of the number of studies conducted in the region, but also through the experience gained during the last few years.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Graciela Rácaro is Senior Director, Clinical Operations, Latin America at PAREXEL International. She is responsible for all clinical and regulatory activities in Latin America. Graciela specialises in drug development and non-clinical and clinical research. Her background includes serving as clinical lead and project manager for Latin American projects as well as global programmes. Prior to joining PAREXEL, Graciela held a clinical management position at Serono International, and previously worked at the clinical research organisation EDYABE and pharmaceutical company Laboratorio Gador, SA. Graciela holds BCh and Pharm degrees from the College of Pharmacy and Biochemistry at the University of Buenos Aires, and completed her Masters in Clinical Research and Clinical Trials Monitoring at the University Maimónides College of Medicine in Buenos Aires. Email: graciela.racaro@parexel.com

 

spacer
Graciela Rácaro
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite

Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement